Systemic exposure and topical efficacy for inhaled fluticasone propionate (FP) in asthmatics

R. Mehta, A. Moore, M. Beerahee, P. Daley-Yates (Durham, United States Of America; Stockley Park West, Uxbridge, Stevenage, United Kingdom)

Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II
Session: Drug delivery and pharmacokinetics II
Session type: Thematic Poster Session
Number: 4552
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
R. Mehta, A. Moore, M. Beerahee, P. Daley-Yates (Durham, United States Of America; Stockley Park West, Uxbridge, Stevenage, United Kingdom). Systemic exposure and topical efficacy for inhaled fluticasone propionate (FP) in asthmatics. Eur Respir J 2010; 36: Suppl. 54, 4552

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Timecourse of action of two inhaled corticosteroids, fluticasone propionate and budesonide
Source: Eur Respir J 2002; 20: Suppl. 38, 308s
Year: 2002

In vivo dose response relation of inhaled fluticasone propionate (FP), adults with bronchial asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 132s
Year: 2004

Once-daily, high-dose inhaled fluticasone propionate and salmeterol in patients having moderate asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 125s
Year: 2004

Salmeterol/fluticasone propionate combination (SFC) versus doubling dose of fluticasone propionate (FP) in children with asthma insufficiently controlled on moderate doses of inhaled corticosteroids
Source: Annual Congress 2010 - Managing asthma and allergic disease in children
Year: 2010


Late Breaking Abstract - Dose responses for topical efficacy and systemic activity, dose equivalence and relative therapeutic index for fluticasone furoate (FF), fluticasone propionate (FP) and budesonide (BUD) in asthmatic subjects.
Source: International Congress 2019 – New towards old therapies in airway diseases
Year: 2019



Efficacy of high-dose inhaled fluticasone propionate in Indian patients having moderate asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 305s
Year: 2002

Comparison of inhaled ciclesonide, fluticasone propinate and fluticasone propionate + salmeterol in maintaining asthma control
Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues
Year: 2009

Initiation of treatment with the salmeterol/fluticasone propionate (FP) combination product is better than inhaled steroid alone (FP) in asthmatic patients symptomatic on short-acting bronchodilator alone
Source: Eur Respir J 2003; 22: Suppl. 45, 410s
Year: 2003

Airway and systemic effects of hydrofluoroalkane formulations of high dose ciclesonide and fluticasone propionate in moderate persistent asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 583s
Year: 2004

Fluticasone furoate (FF), an inhaled corticosteroid (ICS), demonstrates efficacy in asthma patients symptomatic on moderate doses of ICS therapy
Source: Annual Congress 2010 - New treatments for asthma and COPD
Year: 2010

Scientific rationale for inhaled combination therapy with long-acting β2-agonists and corticosteroids
Source: Eur Respir J 2002; 19: 182-191
Year: 2002



Fluticasone furoate (FF), a once-daily inhaled corticosteroid (ICS), demonstrates dose-response efficacy in patients symptomatic on non-steroidal asthma therapy
Source: Annual Congress 2010 - New treatments for asthma and COPD
Year: 2010

Fluticasone furoate (FF), an inhaled corticosteroid (ICS), is efficacious in asthma patients symptomatic on low doses of ICS therapy
Source: Annual Congress 2010 - New treatments for asthma and COPD
Year: 2010

Efficacy of the novel inhaled corticosteroid, fluticasone furoate (FF)/long-acting beta2-agonist, vilanterol (VI) combination in reducing COPD exacerbations
Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights
Year: 2012

Achievement of total control of asthma in clinical practice using the combination of inhaled salmeterol and fluticasone propionate
Source: Eur Respir J 2006; 28: Suppl. 50, 616s
Year: 2006

Effects of inhaled corticosteroids on growth in asthmatic children: A comparision of fluticasone propianate with budesonide
Source: Eur Respir J 2003; 22: Suppl. 45, 133s
Year: 2003

Systemic potency of fluticasone in asthma
Source: Eur Respir J, 55 (3) 2000104; 10.1183/13993003.00104-2020
Year: 2020



Clinical efficacy of once-daily mometasone furoate in children with persistent asthma switched from treatment with fluticasone propionate
Source: Annual Congress 2011 - Airways disease comorbidities and general aspects
Year: 2011

Comparative clinical study of addition theophylline to low-dose inhaled beclomethasone dipropionate and medium-dose inhaled beclomethasone dipropionate in patients with mild-to-moderate persistent asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 98s
Year: 2001

Efficacy of salmeterol/fluticasone propionate MDI versus higher dose fluticasone propionate in adolescent and adult asthmatics uncontrolled on fluticasone propionate alone
Source: Eur Respir J 2003; 22: Suppl. 45, 438s
Year: 2003